Daniel S Kohane

US Patent:

8414912, Apr 9, 2013

Filed:

Dec 11, 2009

Appl. No.:

12/636671

Inventors:

Joseph B. Ciolino - Boston MA, US
Todd R. Hoare - Cambridge MA, US
Daniel S. Kohane - Newton MA, US

Assignee:

Massachusetts Institute of Technology - Cambridge MA
Children's Medical Center Corporation - Boston MA
Massachusetts Eye and Ear Infirmary - Boston MA

International Classification:

A61K 9/00

US Classification:

424429

Abstract:

The present invention relates generally to devices and methods for administering one or more active agents to the eye of a human or animal patient in need thereof, and more particularly to devices for application to the cornea which release active agent to the eye in a controlled manner.

US Patent:

8609733, Dec 17, 2013

Filed:

May 19, 2009

Appl. No.:

12/993622

Inventors:

Daniel S. Kohane - Newton MA, US
Itay Sagie - Haifa, IL

Assignee:

Massachusetts Institute of Technology - Cambridge MA
Children's Medical Center Corporation - Cambridge MA

International Classification:

A01N 37/18
A61K 31/165
C07C 233/00
C07C 235/00
C07C 237/00
C07C 239/00

US Classification:

514626, 564193

Abstract:

Combinations of charged local anesthetics with chemical permeation enhancers have been developed to give long duration block which is selective for sensory block over motor block. The duration of block is greatly prolonged by combining the local anesthetic with a permeation enhancer. The selectivity of sensory over motor block is provided by selecting the concentration of the local anesthetic and the permeation enhancer to provide selective permeability of the sensory and motor neurons to the enhancer.

US Patent:

8642333, Feb 4, 2014

Filed:

Feb 4, 2009

Appl. No.:

12/365604

Inventors:

Lino da Silva Ferreira - Coimbra, PT
Daniel Kohane - Newton MA, US
Robert Langer - Newton MA, US

Assignee:

Massachusetts Institute of Technology - Cambridge MA
Children's Hospital Boston - Boston MA

International Classification:

C12N 5/00
C12N 5/02

US Classification:

435377, 435384, 435383, 435394

Abstract:

The present invention provides a vehicle for delivering various chemicals, compositions and proteins to stem cells and embryoid bodies. The vehicle may be biocompatible and biodegradable polymer microparticles. Typically the particles will contain at least a growth factor for delivery to the embryoid bodies, and generally the growth factor induces differentiation of the cells in the embryoid body along a specific lineage. The present invention also provides methods for directing differentiation of the cells in the embryoid body.

US Patent:

20020150621, Oct 17, 2002

Filed:

Oct 16, 2001

Appl. No.:

09/981020

Inventors:

Daniel Kohane - Newton MA, US
Michael Lipp - Framingham MA, US
Robert Langer - Newton MA, US

International Classification:

A61K009/14

US Classification:

424/486000, 424/488000, 424/484000

Abstract:

Lipid-protein-sugar particles (LPSPs) are provided as a vehicle for drug delivery. Any therapeutic, diagnostic, or prophylatic agent may be encapsulated in a lipid-protein-sugar matrix to form microparticles. Preferably the diameter of the LPSP ranges from 50 nm to 10 micrometers. The particles may be prepared using any known lipid (e.g., DPPC), protein (e.g., albumin), or sugar (e.g., lactose). Methods of preparing and administering the particles are also provided. Methods of providing a nerve block are also provided by administering LPSPs with a local anesthetic (e.g., bupivacaine) within the vicinity of a nerve.

US Patent:

20020150626, Oct 17, 2002

Filed:

Oct 16, 2001

Appl. No.:

09/981460

Inventors:

Daniel Kohane - Newton MA, US
Daniel Anderson - Framingham MA, US
Robert Langer - Newton MA, US

International Classification:

A61K048/00
A61K009/16
A61K009/50

US Classification:

424/493000, 514/044000

Abstract:

Lipid-protein-sugar particles (LPSPs) are provided as a vehicle for the delivery of nucleic acids. Any polynucleotide (e.g., DNA, RNA) may be encapsulated in a lipid-protein-sugar matrix to form microparticles. Preferably the diameter of the LPSP ranges from 50 nm to 10 micrometers. The particles may be prepared using any known lipid (e.g., DPPC), protein (e.g., albumin), or sugar (e.g., lactose). Methods of preparing the particles and administering the particles for gene therapy are also provided. Preferably the methods of preparing the LPSPs do not significantly damage the polynucleotide to be delivered.

US Patent:

20050123596, Jun 9, 2005

Filed:

Sep 23, 2004

Appl. No.:

10/948981

Inventors:

Daniel Kohane - Newton MA, US
Daniel Anderson - Framingham MA, US
Robert Langer - Newton MA, US
William Haining - Newton MA, US
Lee Nadler - Newton MA, US

International Classification:

A61K009/127
C12N015/88
A61K048/00
A61K009/14

US Classification:

424450000, 424489000, 514044000, 435458000

Abstract:

Microparticles that are designed to release their payload when exposed to acidic conditions are provided as a vehicle for drug delivery. Any therapeutic, diagnostic, or prophylatic agent may be encapsulated in a lipid-protein-sugar or polymeric matrix including a pH triggering agent to form pH triggerable microparticles. Preferably the diameter of the pH triggered microparticles ranges from 50 nm to 10 micrometers. The matrix of the particles may be prepared using any known lipid (e.g., DPPC), protein (e.g., albumin), or sugar (e.g., lactose). The matrix of the particles may also be prepared using any synthetic polymers such as polyesters. Methods of preparing and administering the particles are provided. Methods of immunization, transfection, and gene therapy are also provided by administering pH triggerable microparticles.

US Patent:

20050202093, Sep 15, 2005

Filed:

Dec 2, 2003

Appl. No.:

10/727032

Inventors:

Daniel Kohane - Newton MA, US
Robert Langer - Newton MA, US

International Classification:

A61K009/14
A61K009/127

US Classification:

424489000, 424450000

Abstract:

Controlled release of pharmaceutical agents using microspheres or other controlled release systems are used to treat disease state characterized by aberrant electrical activity in excitable tissue. For the treatment of epilepsy, agents useful in the treatment of epilepsy may be delivered to the patient at the site of seizure origin to control seizure activity in a time release manner. The inventive system may also be useful in the treatment of cardiac arrhythmias and pre-term labor. Particularly useful pharmaceutical compositions comprising a site 1 sodium channel blocker are also provided.

US Patent:

20080069857, Mar 20, 2008

Filed:

Apr 12, 2007

Appl. No.:

11/734537

Inventors:

Yoon Yeo - Lafayette IN, US
Taichi Ito - Aoba, JP
Robert Langer - Newton MA, US
Daniel Kohane - Newton MA, US
George Kodokian - Kennett Square PA, US

International Classification:

A61K 9/14
A61K 31/717
A61P 43/00
A61K 31/721

US Classification:

424426000, 424489000, 424501000, 514057000, 514058000

Abstract:

The present invention provides compositions and methods for inhibiting adhesions. The methods involve administering solutions containing hydrogel precursors such as polysaccharide derivatives, e.g., derivatives of hyaluronic acid, cellulose, or dextran, to a subject at a site where adhesions may form, e.g., as a consequence of surgery, injury, or infection. The hydrogel precursors, e.g., polysaccharide derivatives, become crosslinked following their administration to form a hydrogel that maintains tissue separation. In certain embodiments of the invention one or both solutions contains particles, e.g., polymeric nanoparticles or microparticles, so that a composite hydrogel containing the particles is formed. The solution(s), particle(s), or both, may contain a biologically active agent such as an agent that contributes to inhibiting adhesions. The biologically active agent may be covalently attached to a hydrogel precursor.